$2.67T
Total marketcap
$50.11B
Total volume
BTC 49.92%     ETH 17.07%
Dominance

Orient EuroPharma Co., Ltd. 4120.TWO Stock

41.5 TWD {{ price }} -0.598802% {{change_pct}}%
COUNTRY
Taiwan
Market Cap
3.6B TWD
LOW - HIGH [24H]
41.45 - 42 TWD
VOLUME [24H]
9.53K TWD
{{ volume }}
P/E Ratio
138.33
Earnings per share
0.3 TWD

Orient EuroPharma Co., Ltd. Price Chart

Orient EuroPharma Co., Ltd. 4120.TWO Financial and Trading Overview

Orient EuroPharma Co., Ltd. stock price 41.5 TWD
Previous Close 38.6 TWD
Open 38.65 TWD
Bid 38.35 TWD x 0
Ask 38.4 TWD x 0
Day's Range 38.35 - 38.65 TWD
52 Week Range 32.4 - 41.55 TWD
Volume 50.97K TWD
Avg. Volume 79.98K TWD
Market Cap 3.33B TWD
Beta (5Y Monthly) N/A
PE Ratio (TTM) N/A
EPS (TTM) 0.3 TWD
Forward Dividend & Yield 0.85 (2.19%)
Ex-Dividend Date July 18, 2022
1y Target Est N/A

4120.TWO Valuation Measures

Enterprise Value 6.99B TWD
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 0.70217615
Price/Book (mrq) 1.087203
Enterprise Value/Revenue 1.476
Enterprise Value/EBITDA 450.347

Trading Information

Orient EuroPharma Co., Ltd. Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 12.86%
S&P500 52-Week Change 20.43%
52 Week High 41.55 TWD
52 Week Low 32.4 TWD
50-Day Moving Average 37.76 TWD
200-Day Moving Average 36.51 TWD

4120.TWO Share Statistics

Avg. Volume (3 month) 79.98K TWD
Avg. Daily Volume (10-Days) 68.9K TWD
Shares Outstanding 86.75M
Float N/A
Short Ratio N/A
% Held by Insiders 65.12%
% Held by Institutions 0.45%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio N/A
Last Split Factor 1160:1000

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -6.46%
Operating Margin (ttm) -3.56%
Gross Margin 43.50%
EBITDA Margin 0.32%

Management Effectiveness

Return on Assets (ttm) -1.019%
Return on Equity (ttm) -7.97%

Income Statement

Revenue (ttm) 4.74B TWD
Revenue Per Share (ttm) 54.66 TWD
Quarterly Revenue Growth (yoy) 0.59%
Gross Profit (ttm) 2.03B TWD
EBITDA 15.53M TWD
Net Income Avi to Common (ttm) -306532992 TWD
Diluted EPS (ttm) -3.53
Quarterly Earnings Growth (yoy) 18.09%

Balance Sheet

Total Cash (mrq) 2.08B TWD
Total Cash Per Share (mrq) 23.92 TWD
Total Debt (mrq) 5.12B TWD
Total Debt/Equity (mrq) 138.2 TWD
Current Ratio (mrq) 1.128
Book Value Per Share (mrq) 35.274

Cash Flow Statement

Operating Cash Flow (ttm) -285428992 TWD
Levered Free Cash Flow (ttm) -275277504 TWD

Profile of Orient EuroPharma Co., Ltd.

Country Taiwan
State N/A
City Taipei
Address No. 368, Fu Hsing South Road
ZIP 106
Phone 886 2 2755 4881
Website https://www.oepgroup.com
Industry Drug Manufacturers-Specialty & Generic
Sector(s) Healthcare
Full Time Employees N/A

Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, immunology, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk and nutritional supplements under the Karihome, Babecare, and Ostricare brands; and healthcare supplements, such as thermal water for the treatment of oral and periodontal diseases under the Buccotherm name. In addition, the company offers essences, creams, lotions, eye creams, facial treatment toners, and skin repairing essences under the AGLab name; skincare oils, body lotions, and dry skin gels under the Bio-Oil name; and children skincare products under the Mister Baby brand, as well as operates ISISPHARMA, a dermatology laboratory specialized in the development and distribution of dermo-cosmetic products. Further, it engages in the research and development of Multikine, an immunotherapy drug for head and neck cancer, which is in Phase III clinical study; NC-6004, a platinum-based micelle chemotherapeutic drug that is in Phase III clinical study; ASC-J9, a molecular chemical entity drug that has completed Phase IIb clinical study for androgen receptor degradation; and 2ccPA, a derivative of phospholipid to patients with symptomatic osteoarthritis of the knee, which is in Phase I clinical trail. The company was founded in 1982 and is based in Taipei, Taiwan.

Q&A For Orient EuroPharma Co., Ltd. Stock

What is a current 4120.TWO stock price?

Orient EuroPharma Co., Ltd. 4120.TWO stock price today per share is 41.5 TWD.

How to purchase Orient EuroPharma Co., Ltd. stock?

You can buy 4120.TWO shares on the Taipei Exchange exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Orient EuroPharma Co., Ltd.?

The stock symbol or ticker of Orient EuroPharma Co., Ltd. is 4120.TWO.

Which industry does the Orient EuroPharma Co., Ltd. company belong to?

The Orient EuroPharma Co., Ltd. industry is Drug Manufacturers-Specialty & Generic.

How many shares does Orient EuroPharma Co., Ltd. have in circulation?

The max supply of Orient EuroPharma Co., Ltd. shares is 86.75M.

What is Orient EuroPharma Co., Ltd. Price to Earnings Ratio (PE Ratio)?

Orient EuroPharma Co., Ltd. PE Ratio is 138.33333000 now.

What was Orient EuroPharma Co., Ltd. earnings per share over the trailing 12 months (TTM)?

Orient EuroPharma Co., Ltd. EPS is 0.3 TWD over the trailing 12 months.

Which sector does the Orient EuroPharma Co., Ltd. company belong to?

The Orient EuroPharma Co., Ltd. sector is Healthcare.